TNBC accounts for approximately 10 to 15% of breast cancer cases and is associated with higher disease recurrence and worse prognosis compared to other breast cancer subtypes. These data were featured during an oral presentation (GS1-05) at the 2021 San Antonio Breast Cancer Symposium (#SABCS21). TOKYO & MUNICH & BASKING RIDGE, N.J., December 07, 2021-( BUSINESS WIRE)-New data from the TROPION-PanTumor01 phase 1 trial of datopotamab deruxtecan (Dato-DXd), a TROP2 directed DXd antibody drug conjugate (ADC) being developed by Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca (LSE/STO/Nasdaq: AZN), continue to show encouraging durable tumor response and disease control in patients with metastatic triple negative breast cancer (TNBC) with disease progression following standard treatment. Updated data from the TNBC cohort of the TROPION-PanTumor01 phase 1 trial of Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan featured as oral presentation at SABCS
0 kommentar(er)
